Tag Archives: Citius Pharmaceuticals

Citius Announces Its Intention to Spin-Off I/ONTAK

Posted on May 25, 2022 by Stephen Percoco

Earlier today, Citius Pharmaceuticals issued a press release announcing its intention to spin-off its late stage oncology candidate, I/ONTAK, to a new, standalone publicly-traded company. In making the announcement, the company said that it believed that the market has not … Continue reading →

Posted in CTXR, Health Care | Tagged | Leave a comment

Citius Pharma 22Q1 Update

Posted on April 26, 2022 by Stephen Percoco

Citius Pharmaceuticals (CXTR) is a specialty pharmaceutical company focused on the development of five potential products: (1) Mino-Lok, an antibiotic lock solution to treat and salvage infected central venous catheters (CVCs) in patients with catheter-related bloodstream infections (CRBSIs); (2) I/ONTAK, … Continue reading →

Posted in CTXR, Health Care | Tagged | Comments Off on Citius Pharma 22Q1 Update

Citius Pharma Raises $71 million in Equity Unit Offering

Posted on March 23, 2021 by Stephen Percoco

Citius Pharmaceuticals (CXTR) is a specialty pharmaceutical company focused on the development of four potential products: (1) Mino-Lok, an antibiotic lock solution to treat and salvage infected central venous catheters (“CVCs”) in patients with catheter-related bloodstream infections (“CRBSIs”); Halo-Lido, a … Continue reading →

Posted in CTXR, Health Care | Tagged , | Comments Off on Citius Pharma Raises $71 million in Equity Unit Offering